Compare BV & SGP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BV | SGP |
|---|---|---|
| Founded | 1939 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 932.9M |
| IPO Year | 2018 | N/A |
| Metric | BV | SGP |
|---|---|---|
| Price | $11.50 | $22.52 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $14.50 | ★ $45.00 |
| AVG Volume (30 Days) | ★ 520.7K | 100.8K |
| Earning Date | 05-06-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.61 | N/A |
| Revenue Next Year | $1.90 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.06 | $22.41 |
| 52 Week High | $17.11 | $30.56 |
| Indicator | BV | SGP |
|---|---|---|
| Relative Strength Index (RSI) | 36.80 | 31.50 |
| Support Level | $11.27 | N/A |
| Resistance Level | $13.19 | $29.83 |
| Average True Range (ATR) | 0.33 | 1.78 |
| MACD | -0.02 | -0.39 |
| Stochastic Oscillator | 17.73 | 10.49 |
BrightView Holdings Inc is a provider of commercial landscaping services in the United States. The company provides commercial landscaping services, landscape maintenance, and enhancements to tree care and landscape development. It operates through two segments namely Maintenance Services, and Development Services. The Maintenance Services are self-performed through a national branch network and are route-based in nature. It includes mowing, gardening, mulching and snow removal, water management etc. And Development Services are comprised of sophisticated design, coordination, and installation of landscapes at recognizable corporate, athletic, and university complexes. The company generates a majority of its revenue from Maintenance Services.
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.